Evaluation of the Efficacy of MACitentan in the Treatment of CoronaryMICrovascular Angina (MACMIC)

Launched by CHINA-JAPAN FRIENDSHIP HOSPITAL · Feb 1, 2025

Keywords

ClinConnect Summary

This clinical trial, called MACMIC, is studying a medication named macitentan to see if it can help people with coronary microvascular angina (MVA), a condition that causes chest pain and can lower quality of life due to poor blood flow in the heart's small blood vessels. Currently, there are no effective treatments for MVA, and this trial aims to find out if macitentan can improve heart function and relieve chest pain symptoms in patients. The study will use a special method to measure blood flow in the heart, allowing researchers to understand how well macitentan works and monitor any side effects.

To be eligible for this trial, participants need to be between 18 and 75 years old, have typical angina symptoms, and have certain test results showing reduced blood flow in their heart without significant blockages in larger blood vessels. People with severe heart or kidney diseases, pregnant or breastfeeding women, and those who have participated in other drug studies recently will not be able to join. Participants can expect to receive close monitoring throughout the study, and their experiences will help provide valuable information on the safety and effectiveness of macitentan for treating this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-75 years old.
• • With typical angina symptoms.
• • Excluding obstructive coronary lesions (coronary stenosis ≤50% or FFR ≥0.8) by CAG.
• • Coronary microcirculatory function CFR\<2.5 and/or IMR\>25 assessed by temperature dilution method.
• Exclusion Criteria:
• • Pregnant or lactating women.
• • History of heart attack within the last 90 days.
• • Severe heart disease (e.g., moderate to severe heart failure, severe heart valve disease).
• • Severe renal impairment (GFR \<30 ml/min/1.73m2).
• • Severe liver disease (Child-Pugh class C).
• • Moderately severe anaemia (haemoglobin concentration \<90 g/L).
• • Participation in another drug intervention trial study within the last 90 days.